The absence of a gold standard to determine when antibiotics induce a sterilizing cure has confounded the development of new approaches to treat pulmonary tuberculosis (PTB). We detected positron emission tomography and computerized tomography (PET-CT) imaging response patterns consistent with active disease, along with the presence of Mycobacterium tuberculosis (MTB) mRNA in sputum and bronchoalveolar lavage samples, in a substantial proportion of adult, HIV-negative patients with PTB after a standard 6-month treatment plus 1 year follow-up, including patients with a durable cure and others who later developed recurrent disease. The presence of MTB mRNA in the context of nonresolving and intensifying lesions on PET-CT images might indicate ongoing transcription, suggesting that even apparently curative treatment for PTB may not eradicate all of the MTB bacteria in most patients. This suggests an important complementary role for the immune response in maintaining a disease-free state. Sterilizing drugs or host-directed therapies, and better treatment response markers, are probably needed for the successful development of improved and shortened PTB-treatment strategies.
a r t i c l e s Currently there is no absolute measure of a sterilizing cure for PTB. The current standard treatment period of 6 months was determined by acceptable rates of treatment failure and disease recurrence after discontinuation of chemotherapy 1 . The global rate of unsuccessful treatment in HIV-negative patients with drug-sensitive (DS) tuberculosis (TB) is 12% (ref. 2) . In recently published multinational trials, relapse rates within 12-24 months after successful standard treatment ranged from 2.6% to 9.7% (refs. [3] [4] [5] [6] [7] . Shortening treatment is also a major aim of anti-TB drug development 8 . Three trials 3, 4, 6 introduced an experimental 4-month treatment arm, which yielded significantly increased relapse rates even though the rate of sputum culture conversion to negative by month 2 were improved in the interventional arm 3, 4, 6, 9, 10 . Thus MTB may persist in lung tissue for months to years after culture negativity has been achieved through antibiotic treatment.
In contrast to sputum culture conversion, lung lesions-as seen on chest X-ray (CXR) or computed tomography (CT) images-often persist long after the end of successful treatment 11, 12 . Post-TB lung impairment, which contributes to the majority of TB-related disability burden 13 , commonly causes persistent symptoms and signs after a microbiologically confirmed cure [14] [15] [16] [17] [18] [19] [20] . These factors contribute to uncertainty when defining a sterilizing cure and greatly increase the complexity of developing new treatments.
Some subpopulations of slow-replicating MTB are naturally tolerant to all TB drugs 21 , leading to persistent, viable, nonculturable MTB. This was demonstrated in mice, in which MTB mRNA transcripts (shown to be absent in dead bacteria in vitro) were detected in culture-negative tissue from mice that were necropsied after 14 weeks of isoniazid (INH) and pyrazinamide treatment. High-dose steroid treatment induced bacteriological relapse in 21 of 23 mice that were followed up on after treatment 22 . The presence of mRNA could suggest transcriptionally active bacteria, as MTB mRNA has a very short halflife (on average 9.5 min in vitro), although stabilization of transcripts does occur after intact MTB is exposed to stress such as cold shock or hypoxia; therefore, the half-life of MTB mRNA in vivo is not known 23 . The retention of low-abundance mRNA and a relative increase in the amount of noncoding RNA in dormant MTB have been shown in in vitro persistence induced by potassium depletion and rifampicin exposure, and these may have a role in early reactivation 24 . To date, however, persistent bacteria have not been observed in humans.
PET-CT is a well-established technique in the management of cancer. Uptake of 18 F-labeled fluorodeoxyglucose ([ 18 F]FDG), the most widely used PET tracer, reflects glucose metabolism, with increased uptake being observed in areas of inflammation [25] [26] [27] . PET images are viewed alongside corresponding CT images, which reflect tissue density and provide anatomical information.
In mouse, rabbit and primate models, [ 18 F]FDG PET-CT has been used to accurately show the progression of MTB disease. These studies suggest that there is some correlation between relative [ 18 F]FDG uptake in a lesion and the bacterial numbers in the lesion [28] [29] [30] [31] [32] . Individual lesions can improve or deteriorate in apparent contrast to the overall trend of disease progression in the host, with or without antibiotic treatment, pointing to a dynamic and localized nature of TB versus host interactions [28] [29] [30] [31] . Human PET-CT studies have shown promise in monitoring the effects of different anti-TB drug regimens and seem to be superior to CT imaging alone [33] [34] [35] [36] [37] [38] . More background on PET-CT is provided in Supplementary Note 1.
The present study was conducted to track changes in PET-CT imaging before, during and after antibiotic treatment, and to correlate radiologic findings with microbiologic data, in South African and South Korean patients with PTB. We report a notable heterogeneity in radiological responses among patients, with ongoing inflammation after curative treatment in the majority. In the South African cohort, we also detected, using qRT-PCR, the presence of several different mycobacterial mRNA transcripts in sputum and bronchoalveolar lavage (BAL) samples at the end of successful treatment outcomes.
RESULTS

Patient demographics and treatment
In Cape Town, South Africa, we recruited 99 HIV-uninfected, nondiabetic, adult patients with PTB at diagnosis (Dx) and followed them during the course of treatment. Ninety-five patients had DS strains. Of these, 72 received a standard 6-month regimen, whereas 23 patients received an extended 8-month regimen (owing to previous episode(s) of TB in 22 patients and delayed smear conversion in one). Two patients had INH-monoresistant TB and were treated for 6 and 12 months, respectively, and two patients with multidrugresistant (MDR) TB were treated for 2 years on individualized regimens. Month 6 (M6) was selected as a fixed time point for doing PET-CT scans and collecting sputum, consistent with current World Health Organization (WHO) treatment guidelines 39 .
Of the 99 patients, 8 remained culture positive at M6 and failed treatment, 76 converted to MTB-negative sputum culture and maintained cure, and 12 became sputum culture negative but were diagnosed with recurrent PTB within 2 years after treatment completion (EOT + 2y). Supplementary Data Set 1 shows a summary of 'time to re-diagnosis' and the supporting results. Initial treatment outcome was un-evaluable (UE) for three patients owing to contaminated cultures. All of the patients on the extended regimen were culture negative from M6 to EOT. Fourteen patients took fewer than approximately 80% of their treatment dosages during the 6-month period, which is regarded to be a poor rate of adherence in most clinical trial designs 3, 6 . The 'failed' treatment group included four patients with poor treatment adherence and one with MDR disease. Most of the patients (96%) reported improvement during treatment, but residual chronic symptoms were often encountered. The most frequent symptoms were coughing (in 47 patients), dyspnoea (in 21 patients) and low body-mass index (in 24 patients). Table 1 provides a summary of patient demographics, treatment adherence, as well as culture and GeneXpert MTB-Rif (a nucleic acid amplification test to detect MTB DNA plus resistance to rifampicin; hereafter referred to as Xpert) results.
We also recruited 14 HIV-negative patients with PTB from Masan, South Korea, including three cases with MDR TB and two with monoresistance to rifampicin. Twelve were cured (culture converted within 6 months), one had an un-evaluable outcome, and one had culture-confirmed recurrence after the initial cure. The study design and research procedures are detailed in Figure 1 .
Month 6 PET-CT findings in 99 South African patients
All of the patients had [ 18 F]FDG PET-CT lung scans performed at Dx, month 1 (M1) and M6 of TB treatment. We compared scans taken at M6 to those taken at Dx and identified three distinct response patterns: resolved, improved and mixed. A resolved response pattern refers to minimal or no increased [ 18 F]FDG uptake as compared to uptake by the surrounding healthy lung tissue, regardless of structural abnormalities on the CT images. Improved scans show decreased intensity for all lesions, as compared to the baseline scan, but had one or more lesion(s) with increased uptake as compared to background and reference structures. Mixed responses show at least one new [ 18 F]FDG-avid lesion, or at least one lesion with increased [ 18 F]FDG uptake (intensified), as compared to the baseline scan. Representative cases are shown in Figure 2 .
Unexpectedly, only 14 patients (14%) had a resolved pattern on their M6 scan ( Fig. 2a) , and in 51 patients (52%) we found an improved response on a M6 scan ( Fig. 2b) . A mixed response ( Fig. 2c) was (17 cases) , enlarged hilar lymph nodes (three cases) and pleural-based infiltrates (one case). Treatment outcome was associated with scan-response pattern ( Fig. 3a ; P < 0.01), with a mixed response found in all of the patients in the failed treatment group. Neither a mixed response nor a high maximum lesion intensity, however, was specific to a poor outcome, and 21 cured patients (28%) had a mixed response, whereas 55 (72%) still had M6 lesions with moderate to very high intensity, which would be compatible with the intensity range found at Dx.
PET-CT findings in 14 South Korean patients
All 14 patients had PET-CT scans at Dx, M1 and M6. We applied the same criteria mentioned above and found seven patients with mixed (50%), six with improved and only one with resolved scan patterns at the M6 time point. Eleven patients had moderate to very-high-intensity lesions at M6. A summary of scan findings is in Figure 3b ; detailed demographical data are in Supplementary Data Set 2, and representative PET-CT images are in Supplementary Note 2.
PET-CT findings 1 year after completion of treatment
In view of the findings in the M6 scans, we added a fourth scan at 1 year after the end of treatment (EOT + 1y) for 50 South African patients who had not yet passed this time point and who were cured at M6. Eight of these 50 patients were diagnosed with recurrent disease by healthcare providers within 2 years of treatment completion, five before the EOT + 1y scan and three subsequently. The other 42 maintained the cured phenotype. When we compared the EOT + 1y scans to the M6 scans, we observed improvement in the size and intensity of most of the residual lesions ( Fig. 3c and representative images in Fig. 4 ). Only 32% of the EOT + 1y scans, however, showed completely resolved lesions. The remaining 68% had residual [ 18 F]FDG-avid lesion(s). In half of these we found improvement of all lesions, whereas the other 34% had a mixed lesion response, when compared to the M6 scan. Morphology of new [ 18 F]FDG-avid lesions at EOT + 1y included nodular infiltrates (in four cases), hilar lymph nodes (one case), cavitation (two cases), consolidation (two cases) or lesions with combined morphology (three cases). Residual lesions at M6 showing similar or more intense [ 18 F]FDG uptake at EOT + 1y included consolidation (two cases), cavitation (four cases) and nodules (two cases). All three patients who developed recurrent PTB after EOT + 1y had mixed scan outcomes at this time point, and no patients diagnosed with recurrence had resolved scans.
DNA and mRNA in M6 sputum
Patients with an Xpert + M6 sputum were more likely to have an unfavorable clinical outcome (7/8 failed treatment, 6/12 recurrent and 16/65 cured; P < 0.001) and M6 PET-CT lesions with high to very high intensity (P = 0.04) ( Table 1 ; in-depth analysis of Xpert cycle values to be discussed in S. Shenai & D. Alland, PLoS ONE (in the press)).
We performed mRNA detection assays on sputum obtained at the M6 time point from 75 consecutive participants (60 cured, 4 failed treatment, 9 recurrent and 2 un-evaluable) who produced an adequate volume of sputum, as well as on sputum from 20 community controls and from five control subjects with lung disease other than TB (OLD). We assayed the sputum samples for 13 MTB-specific mRNA targets (85B, dosR, hspX (acr), pstS1, carD, nuoB, tgS1, TB8.4, TB31.7, acpM, icL, prcA and rrnAP1).
In the M6 sputum from the 75 patients, at least one MTB mRNA target was detected in 29 patients (39%): 22 (37%) from the cured outcome group, four (100%) from the failed treatment group, two (22%) patients with recurrent PTB and one with an un-evaluable outcome. The most frequently detected transcripts were hspX (acr), acpM and rrn, which were present in 20, 17 and 12 patients' npg a r t i c l e s M6 sputum, respectively. Tgs1 and acpM transcripts were detectable at low levels in one community control each. We performed principal component analysis (PCA) to reduce the dimensions of all of the transcript levels into one variable that indicated mRNA presence. PCA results (Fig. 5a) illustrate that all cases with failed treatment and 22 cured patients still had detectable MTB mRNA in their M6 sputum (transcript values in Supplementary Data Set 3). Two community controls and none of the controls with OLD had low levels of mRNA transcripts (M6 versus controls; Fisher's exact test; P = 0.001). We found a trend for collapsed categories of M6 PET-CT lesion intensity to be correlated with MTB mRNA detection in M6 sputum (P = 0.08).
RNA in end of treatment bronchoalveolar lavage samples
We obtained bronchoalveolar lavage (BAL) samples from the most affected lung segment identified on the PET-CT scans, as well as post-bronchoscopy sputa from 15 consecutive, consenting patients with DS PTB within 3 months after EOT (note: PET-CT scans and sputum were collected at a fixed M6 time point). Treatment duration was 6 months for this group. We also collected BAL samples from ten control patients who were undergoing bronchoscopy as part of a clinical workup for suspected lung cancer. The 15 EOT patients included 13 cured (M6 sputum-culture negative), one recurrent (M6 sputum-culture negative but who became positive again 3 months after treatment) and one failed treatment (M6 sputum-culture positive) case. The ten controls included one patient in whom new active PTB was subsequently diagnosed on the basis of BAL culture (although sputum culture was negative). All other BAL samples and postbronchoscopy sputa were negative for MTB in liquid culture. Cancer was confirmed in five control subjects, whereas three had bacterial infections and one had interstitial fibrosis. Five of these ten control subjects had a positive Quantiferon blood test (suggesting latent TB infection). BAL sample or post-bronchoscopy sputum sample at EOT for 10 of the 15 PTB cases and the new PTB case were Xpert + , and MTB DNA was detected in all EOT BAL samples by qRT-PCR.
We performed blinded mRNA detection assays on all BAL samples. Nineteen MTB-specific mRNA targets (recF, eccD3, menA, iprB, Rv1421, gabD2, Rv1910c, hspX, fadD9, tgs1, fadE34, Rv3675, sodA,  trxB2, rpsJ, rplV, sigI, sigH and rpsK) , which were previously shown to be differentially regulated in stress or persistence 40, 41 , were assayed.
A median of eight mRNA transcripts were positive in the BAL samples from the EOT cases (range 1-19); one MTB mRNA transcript was detected in the BAL sample from three of the five Quantiferon-positive control cases (P < 0.001, EOT versus controls). The target most frequently detected was hspX, which was present in the failed treatment and new diagnosis cases, as well as in 14 of the cured patients, but in none of the controls. HspX has previously been linked to longterm persistence 42 . In the BAL sample from the patient in the control group with the newly diagnosed PTB, we detected five transcripts. We used PCA to summarize mRNA positivity ( Fig. 5b ; transcript values per patient in Supplementary Data Set 4).
DISCUSSION
Here we show ongoing inflammation, as detected by PET-CT, in the majority of-and the presence of MTB mRNA and DNA in respiratory samples from a substantial number of-culture-negative South African patients with PTB at the end of treatment. Similar PET-CT response patterns were seen in a smaller South Korean cohort, for whom RNA data were unavailable.
Our study confirms the persistence of TB lung lesions, which were previously described on CT images and CXRs 11, 12 . We also frequently found residual symptoms or signs in keeping with lung impairment after treatment, similar to those described in other reports on post-TB lung sequelae [14] [15] [16] [17] [18] [19] [20] . In addition, although most lesions improved and scan-response patterns showed an association with clinical outcomes, PET imaging showed that the majority of patients still had lesions with an ongoing inflammatory response, and roughly one-third of patients showed intensified or new lesions. These dynamic patterns were found after anti-TB treatment and even a year later, regardless of drug sensitivity, sustained culture conversion or clinical cure. A European study of 35 patients with pulmonary or extra-pulmonary TB reported persistent PET-CT lesions in 15 patients and progressive lesions in four patients after a mean treatment duration of 16.1 months 37 , whereas a Japanese study reported resolution of all lesions in eight patients with DS PTB after 12 months of treatment 35 . It is not clear whether the favorable scan outcome in the Japanese cohort is related to extent of disease, treatment duration, lower infection pressure, or better living standards and health.
[ 18 F]FDG uptake only reflects the increased metabolic activity associated with inflammation and does not necessarily imply active MTB infection. After the successful treatment of bacterial or pneumocystis pneumonia, however, radiological lesions typically resolve within 6 weeks 43 , and the relative intensity of [ 18 F]FDG uptake by PET has shown correlation with MTB bacterial load in animal lesions 29 . PTBrelated pathology is the most concordant with our PET-CT findings, considering the underlying morphology of individual lesions and the absence of clinical findings supporting other diagnoses. Persistent antigens, which are associated with dead MTB, might lead to increased [ 18 F]FDG avidity after treatment, but it is unlikely to cause veryhigh-intensity, intensified or new lesions. PET-CT imaging provides insight into the local host response, and further research is required to unravel the interaction between the local host response and MTB. Our results confirmed the high Xpert-positivity rate previously reported in culture-negative sputum samples and noted an even higher rate in bronchoscopy samples 44, 45 . In addition, we detected MTB mRNA in 35% of culture-negative sputum samples at M6 and in all BAL samples taken from 15 patients with PTB at EOT. Alpha-crytallin (hspX), which is linked to long-term MTB persistence 42 , was present in 20 (27%) of the M6 sputum samples and 14 (93%) of the EOT BAL samples, whereas it was absent in sputum and BAL samples from all of the controls at a single time point. The detection of MTB mRNA in two separate types of respiratory samples suggests either ongoing transcription (based on the short half-life of MTB mRNA 14, 15 ) or persistence of stabilized mRNA (as seen in nonreplicating MTB in vitro 24 ). Although persistent MTB DNA in intact, nonviable bacteria may explain Xpert positivity, the same is unlikely to apply to MTB mRNA. This is the largest study examining PET-CT scans and mRNA after treatment for PTB; however, it is a relatively small study, with a small number of unfavorable outcomes and without differentiation between relapse and re-infection. Other studies in Cape Town reported similar recurrence rates, and if the recurrence occurred within 2 years of EOT, then approximately 66% of these were due to relapse 46, 47 . We could not establish whether the positivity of some mRNA transcripts in the sputum of two controls could be the result of latent or subclinical MTB infection or of transient MTB excretion after recent exposure 48, 49 . We also could not eliminate the possibility that even pre-validated probes show cross-reactivity. However, in a blinded test, the EOT patients scored more MTB transcriptional signals more frequently than the community controls, and most probes did not show any positivity in the controls. The extent to which the stochastic detection of low levels of MTB mRNA in individuals in communities with a high TB burden represents true detection of MTB in individuals without manifestations of clinical TB has yet to be determined.
The paradox that some samples were Xpert negative but mRNA positive could be explained by the different sensitivities of the assays; the mRNA isolation procedures concentrate specimens before the assays, and usually there are many copies of an mRNA species per genome copy. We also observed Xpert-positive, mRNA-negative specimens, possibly owing to MTB DNA's greater stability in both dead and live cells. In BAL samples, however, we observed a good concordance between mRNA and DNA detection, as the BAL samples were from a targeted sampling of the affected lobe and were processed immediately and concentrated. The presence of DNA and mRNA in all of the BAL samples suggests that both are usually present in parenchyma but may be variable in sputum. We found an excellent correlation between MTB mRNA in BAL samples and clinical TB status (P < 0.001; Supplementary Note 3) .
Our study was exploratory, and the patients were investigated intensively, allowing complementary results from different tests. In summary, we describe a marked heterogeneity in treatment responses of individual PET-CT lesions and in the presence of MTB mRNA in sputum and BAL samples from a substantial number of cured patients at the end of treatment. Although MTB mRNA stability remains a possible explanation for its presence in intact bacteria, we suggest that viable MTB, with the potential to elicit a host response, often persist even after clinically curative treatment. The higher relapse rates in patient groups with impaired immunity 7,50-52 support the concept that a competent immune response has an important complementary role in the ultimate control of residual bacteria after completion of antibiotic treatment. The nature of host-pathogen interactions and its association with poor treatment outcome and post-TB lung impairment need to be investigated in future studies. This will facilitate the development of sterilizing drug or host-directed therapies, and of better treatment response markers for improved or shortened PTB treatment strategies.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. a r t i c l e s ONLINE METHODS Recruitment and follow-up, South Africa. Ethical approval was obtained from the Stellenbosch University Human Research Ethics Committee (registration number N10/01/013). In total, 131 HIV-uninfected adults with newly diagnosed PTB, as confirmed by sputum culture, were recruited after informed consent between April 2010 and April 2013 at primary healthcare clinics (PHCs) in Cape Town. Of these patients, 32 were excluded for missed scan visits due to technical reasons (7) , patient decision (8), loss to follow up (6), sputum culture negativity at diagnosis (8) and severe co-morbidity (3).
Sputum specimens for mycobacteria growth indicator tube (MGIT) culture with speciation and additional clinical information were collected at day 0 and weeks 1, 4, 8, 12, and 24 for all participants, and an additional culture was collected at week 20 for the last 64 patients who completed the study. Of the 99 patients who completed the study time points (including 60 males and 39 females), 85 patients were also available for a formal follow-up visit 1 year after the end of treatment, whereas the other cured patients were screened by telephonic interview and by review of medical records and results. The screen was repeated for all participants 2 years after the end of treatment. Patients' clinical outcomes were classified as 'cured' if they proved and maintained sputum culture negativity by month 6 (M6), 'failed' if the M6 culture was still positive, 'un-evaluable' if contamination caused uncertainty in outcome, and 'recurrent' if they were restarted on TB treatment by healthcare providers in the 2 years after completion of the initial treatment. Of the recurrent patients, two were culture-confirmed, five were confirmed by both Xpert with supporting acidfast bacillus (AFB) testing for smear positivity by direct microscopy, three were Xpert negative at month 6 but converted back to positive, and two remained Xpert positive for more than 6 months but complained of increased symptoms. None of the un-evaluable group was diagnosed by healthcare providers with recurrent PTB before EOT + 2y.
Spoligotyping was performed on sputum cultures from Dx and M6 for patients who failed treatment. In six of eight cases, identical strains were found, whereas the remaining two patients had different strains at Dx and M6. This may be due to reinfection 53 during the treatment phase, or concurrent infection with different strains than at Dx 54, 55 .
Sixty-six asymptomatic community controls and 13 controls diagnosed with infective or inflammatory lung diseases other than PTB (other lung disease; OLD) were recruited from the same high-TB-incidence communities. Of this group, 20 community (9 males and 11 females) and five OLD (2 males and 3 females) consecutively enrolled controls were included in sputum MTB RNA analysis. OLD controls included four cases of pneumonia and one asthma exacerbation case. Active tuberculosis was excluded for all controls based on negative sputum culture and a chest X-ray that was not suggestive of PTB. All of the controls were HIV negative and not on any systemic corticosteroid treatment.
Treatment regimen. All of the patients were subjected to directly observed treatment (DOT) at local healthcare clinics. Seventy-two patients received a standard treatment regimen: a 2-month intensive phase with daily fixed-dose combination tablets (HRZE) of isoniazid (INH), rifampicin (Rif), ethambutol (EMB) and pyrazinamide (PZA), followed by a 4-month continuation phase of daily INH and Rif treatment (currently the standard of care according to the WHO guidelines) 39 . Twenty-three patients received an extended regimen: a 3-month initiation phase of HRZE, with (19) or without (4) additional streptomycin in the first month, and a 5-month continuation phase. In 22 patients, the indication for the extended regimen was previous episode(s) of PTB; for the remaining patient, it was delayed smear conversion. The local guidelines were amended during the study period to a standard 6 months of HRZE treatment for all drug-susceptible cases, resulting in seven patients with previous episode(s) who did not receive extended treatment.
Two patients had INH monoresistance and received 6 months of HRZE with added ofloxacin or 12 months of HRZE, respectively. Two patients with MDR TB received individualized regimens containing kanamycin and terizidone, among other drugs.
Recruitment and follow-up, South Korea. All participants signed informed consent (ethical approval from National Medical Centre Institutional Review board: IRB00008343). 19 culture-positive patients with PTB were recruited at diagnosis in Masan, South Korea. Three patients were lost to follow-up; two decided to leave the study. The 14 patients (including 12 males and 2 females) who completed the scans at Dx, M1 and M6 included three with MDR strains and two with rifampicin monoresistance. Patients with DS PTB were treated with standard HRZE for 6 months, rifampicin-resistant cases were treated for 12 months, and MDR cases were treated for 18 months after culture conversion, on individualized regimens. Patients were followed for 2 years after treatment; one patient was diagnosed with recurrent PTB with a strain different than the one at diagnosis.
Positron emission tomography and computerized tomography (PET-CT).
A 1-week window was allowed for the Dx and M1 scans; a 4-week window was allowed for the M6 and EOT + 1y year scans. Patients fasted for at least 6 h before [ 18 F]FDG administration. According to body weight, 185-259 MBq of [ 18 F]FDG was administered intravenously 60 min before the scan. Scans at baseline were performed from the base of skull to the upper thigh, and from the neck to the upper abdomen (whole lung), at M1, M6 and EOT + 1 yr. The CT scan parameters were set at 120 kV, 100 mAs (no dose modulation), with a 3-mm slice thickness.
CT and PET images were evaluated in collaboration and consensus with a radiologist, a nuclear physician and a pulmonologist. Patient clinical outcomes were not known at the time of reading. Lesion morphology was characterized and measured based on CT images. PET uptake intensity of prominent lesions was measured using the mean and maximum standardized uptake value (SUV) and compared across time points, using the uptake in the right lobe of the liver and the mediastinal aortic blood pool as reference values to account for variability in background uptake 25, [56] [57] [58] [59] [60] [61] [62] .
The most intense lesion of each scan was ranked based on its mean standard uptake value (SUV mean ). The method was adapted from the Deauville grading system (low, moderate and high intensity), which uses the mediastinal blood pool and liver as references 56, 63, 64 . 'None' indicates no increased uptake as compared to that of the surrounding lung tissue. 'Minimal' refers to uptake that is more intense than that of the surrounding lung tissue but less intense than the SUV mean of a 10-mm sphere in mediastinal blood pool. 'Mild' indicates uptake that is more intense than that of the mediastinal blood pool but less than one s.d. below the SUV mean of a 30-mm sphere in the right liver lobe. 'Moderate' indicates uptake similar to that of the liver (between 1 s.d. below SUV mean and 2 s.d. above SUV mean . 'High' refers to uptake that is more intense than that 2 s.d. above the liver SUV mean and less than double the liver SUV mean . 'Very high' refers to an intensity greater than double the liver SUV mean .
Scans were grouped into response patterns by comparing each M6 lesion to the corresponding M1 lesion to summarize the central trend of lesion progression. Resolved response pattern refers to minimal or no increased [ 18 F]FDG uptake as compared to that of the surrounding healthy tissue, regardless of structural abnormalities on the CT image. Improved scans had decreased intensity of all lesions as compared to that at the baseline scan, but they still had one or more lesion(s) with increased uptake as compared to that of the surrounding lung tissue and reference structures. Mixed responses showed at least one new [ 18 F]FDG-avid lesion or at least one intensified lesion as compared to the baseline scan.
MTB RNA in M6 sputum. For transcription, a QuantiFast Multiplex RT-PCR kit (Qiagen) with a primer designed to be specific for each MTB target gene was used. We selected genes that were previously shown to have increased expression under conditions of stress and persistence 40, 41 . 2-ml sputum specimens were collected and added to 2 ml of Trizol (Invitrogen), flash-frozen in liquid nitrogen and stored at −80 °C. For RNA extraction, samples were thawed and spun down at 3500g for 25 min. The supernatant was discarded, and the pellet was resuspended in 1 ml Trizol reagent. The entire content of the tube was transferred into new 2-ml screw cap micro-centrifuge tubes containing 0.5 ml of zirconia-silica beads (diameter, 0.1 mm; MP Biomedicals). Bacteria were disrupted in a Bead Beater (FastPrep Cell Disrupter, FP120) using two 45-s pulses at the maximum speed of 6.5 m/s, incubated on ice for 5 min, and followed by the addition of 250 µl of chloroform and vigorous mixing for 15 s and then a 2-to 3-min incubation at room temperature. Samples were then centrifuged at 12,000g for 5 min, npg and the upper clear phase was transferred carefully to a new tube, mixed with an equal volume of 70% ethanol, applied to an RNeasy mini column (Qiagen) and processed according to the manufacturer's recommendations.
Fourteen mRNA targets (85B, dosR, hspX (acr), pstS1, carD, nuoB, tgS1, TB8.4, TB31.7, acpM, icL, prcA, sigA and rrnAP1) were reverse-transcribed using a QuantiFast Multiplex RT-PCR kit (Qiagen) and a primer specific for each target gene. The conditions for reverse-transcription (RT)-PCR were 50 °C for 50 min and 95 °C for 2 min. The amount of cDNA produced was quantified by real-time PCR with the corresponding molecular beacon. The 10-µl PCR reaction mixture consisted of 1× PCR buffer, 250 µM deoxynucleoside triphosphates, 4 mM MgCl 2 , 0.5 µM each primer, 4 ng/µl molecular beacon and 0.03 U/µl Jumpstart Taq polymerase (Sigma-Aldrich). To normalize the individual reactions, 6-carboxy-X-rhodamine (ROX) was always included as a passive reference dye. PCR reactions were performed in 384-well microtiter plates in an ABI 7900 Prism (Applied Biosystems, Foster City, CA) according to the following parameters: initial denaturation 95 °C for 1 min, then 50 cycles of: denaturation 95 °C for 30 s, annealing 58 °C for 30 s and extension at 72 °C for 15 s. PCR conditions were identical for all assays. The fluorescence was recorded during the annealing step of the assay. The quantity of specific target DNA was determined from the cycle threshold (C t ) value with reference to a standard curve of genomic MTB DNA. The copy numbers of the target standards used ranged from 1 to 10 6 genomic copies per reaction (i.e., 10 fg to 10 ng DNA from CDC 1551 strains). The lower limit of detection for each assay was 10 fg, which is equivalent to 1-5 copies of cDNA. qRT-PCR reactions were performed in triplicate. The mean of each triplicate is used in calculations. The sigA target showed cross-reactivity with non-TB mycobacterial RNA at high concentrations in addition to low-level positivity in four community controls and one control with other lung disease, and it was subsequently dropped from further analysis. Primer sequences are listed in Supplementary Note 4.
RNA in EOT bronchoalveolar lavage samples. Culture from BAL fluid is generally more sensitive than culture from sputum 65, 66 , although the quality of the sample can be variable. An additional high-quality sputum sample is often taken after the procedure 67 . Bronchoscopies were performed on 15 of the patients with PTB within 3 months after the end of their standard treatment (EOT), and BAL fluid and post-bronchoscopy sputa were obtained. MGIT cultures on bronchoscopy samples were allowed extended growth periods (12 weeks). BAL fluid was also collected from ten patients (three males and seven females) suspected of having cancer and undergoing diagnostic bronchoscopies, as controls. We added 15 ml of fresh BAL fluid to 30 ml Trizol and stored it at −80 °C until RNA analysis.
Multiplex real-time RT-PCR transcriptional analysis of sputum and BAL specimens from 14 recently cured and one failed treatment patient. Fluorescencebased qRT-PCR is accepted as a gold standard for gene expression profiling due to its high specificity, sensitivity, accuracy and large dynamic range.
Extraction of total RNA from BAL samples. BAL samples were sent, in a blinded fashion, for MTB RNA analysis via two-step qRT-PCR with validated TaqMan assays developed at Stanford 40, 68 . Total MTB RNA isolated from BAL was reverse-transcribed using random primers and pre-amplified in a controlled multiplex PCR with 743 MTB-specific primer sets targeting corresponding mRNA transcripts as described previously 69 . Finally, we used only 24 gene-specific TaqMan assays for individual gene transcript quantification of multiplex PCR products targeting the genes shown as differentially regulated in stress or persistence based on the available literature 40, 41 . These genes included recF, eccD3, menA, pabC, accD3, iprB, Rv1421, gabD2, Rv1910c, hspX, lipX, fadD9, tgs1, fadE34, Rv3675, sodA, trxB2, rpsJ, rplV, sigI, Rv1255c, sigB, sigH and rpsK 40 .
Samples were thawed, and total RNA was extracted using a glass-matrix tube for cell lysis (Lysing Matrix B, Q Biogene) in a FastPrep FP120 instrument (Bio 101, Thermo Savant) with a speed setting of 6 for three iterations of 30 s, with cooling on ice for 1 min after each iteration. After processing, chloroform was added, followed by separation of the aqueous and organic layers. The aqueous phase containing the RNA was removed to a fresh tube, and the RNA was precipitated overnight at −20 °C after addition of glycoblue (Ambion), 0.1 volume of 5 M ammonium acetate and an equal volume of isopropanol. The resulting RNA pellet was resuspended in 50 µl of RNase-free water and cleaned by three rounds of the RNeasy minicolumn system, interspersed with off-column DNase treatments (Promega RQ1 DNase) 40 .
